Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 131, Issue 13
March 29 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

CLINICAL TRIALS AND OBSERVATIONS
Pevonedistat, a new partner for 5-azacitidine
Clinical Trials & Observations
Amir T. Fathi
View Articletitled, Pevonedistat, a new partner for 5-azacitidine
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Fire behind the fury: IL-18 and MAS
Kenneth L. McClain,Carl E. Allen
View Articletitled, Fire behind the fury: IL-18 and MAS
Lymphoid Neoplasia
ARF way to Ph+ ALL stratification?
Adele K. Fielding
View Articletitled, ARF way to Ph<sup>+</sup> ALL stratification?
TRANSPLANTATION
Treating chronic GVHD-induced fibrosis?
Gerard Socié
View Articletitled, Treating chronic GVHD-induced fibrosis?

BLOOD SPOTLIGHT

B-cell targeting in chronic graft-versus-host disease
Robert Zeiser,Stefanie Sarantopoulos,Bruce R. Blazar
View Articletitled, B-cell targeting in chronic graft-versus-host disease

HOW I TREAT

How I treat myelodysplastic syndromes of childhood
Franco Locatelli,Brigitte Strahm
View Articletitled, How I treat myelodysplastic syndromes of childhood

CLINICAL TRIALS AND OBSERVATIONS

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Clinical Trials & Observations
Ronan T. Swords,Steven Coutre,Michael B. Maris,Joshua F. Zeidner,James M. Foran,Jose Cruz,Harry P. Erba,Jesus G. Berdeja,Wayne Tam,Saran Vardhanabhuti,Iwona Pawlikowska-Dobler,Hélène M. Faessel,Ajeeta B. Dash,Farhad Sedarati,Bruce J. Dezube,Douglas V. Faller,Michael R. Savona
View Articletitled, Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Mouse and human HSPC immobilization in liquid culture by CD43- or CD44-antibody coating
Brief Report
Dirk Loeffler,Weijia Wang,Alois Hopf,Oliver Hilsenbeck,Paul E. Bourgine,Fabian Rudolf,Ivan Martin,Timm Schroeder
View Articletitled, Mouse and human HSPC immobilization in liquid culture by CD43- or CD44-antibody coating
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice
Charlotte Girard-Guyonvarc’h,Jennifer Palomo,Praxedis Martin,Emiliana Rodriguez,Sabina Troccaz,Gaby Palmer,Cem Gabay
View Articletitled, Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice
Supplemental data
Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
Clinical Trials & Observations
Eric S. Weiss,Charlotte Girard-Guyonvarc’h,Dirk Holzinger,Adriana A. de Jesus,Zeshan Tariq,Jennifer Picarsic,Eduardo J. Schiffrin,Dirk Foell,Alexei A. Grom,Sandra Ammann,Stephan Ehl,Tomoaki Hoshino,Raphaela Goldbach-Mansky,Cem Gabay,Scott W. Canna
View Articletitled, Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome
Supplemental data

LYMPHOID NEOPLASIA

Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Clinical Trials & Observations
Anne-Ségolène Cottereau,Annibale Versari,Annika Loft,Olivier Casasnovas,Monica Bellei,Romain Ricci,Stéphane Bardet,Antonio Castagnoli,Pauline Brice,John Raemaekers,Bénédicte Deau,Catherine Fortpied,Tiana Raveloarivahy,Emelie Van Zele,Loic Chartier,Thierry Vander Borght,Massimo Federico,Martin Hutchings,Umberto Ricardi,Marc Andre,Michel Meignan
View Articletitled, Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Supplemental data
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation
Heike Pfeifer,Katharina Raum,Sandra Markovic,Verena Nowak,Stephanie Fey,Julia Obländer,Jovita Pressler,Verena Böhm,Monika Brüggemann,Lydia Wunderle,Andreas Hüttmann,Ralph Wäsch,Joachim Beck,Matthias Stelljes,Andreas Viardot,Fabian Lang,Dieter Hoelzer,Wolf-Karsten Hofmann,Hubert Serve,Christel Weiss,Nicola Goekbuget,Oliver G. Ottmann,Daniel Nowak
View Articletitled, Genomic CDKN2A/2B deletions in adult Ph<sup>+</sup> ALL are adverse despite allogeneic stem cell transplantation
Supplemental data

TRANSPLANTATION

Vitamin A–coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease
Tomohiro Yamakawa,Hiroyuki Ohigashi,Daigo Hashimoto,Eiko Hayase,Shuichiro Takahashi,Miyono Miyazaki,Kenjiro Minomi,Masahiro Onozawa,Yoshiro Niitsu,Takanori Teshima
View Articletitled, Vitamin A–coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease
Supplemental data

LETTERS TO BLOOD

Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies
Clinical Trials & Observations
Brian R. Curtis,Yen-Michael S. Hsu,Nikolai Podoltsev,Jill Lacy,Susanna Curtis,Michael S. Samuel,Kristin Zutavern,Robert A. DeSimone,Daniel W. Bougie,Richard H. Aster
View Articletitled, Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies
Supplemental data
In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers
Heiko Rühl,Franziska Isabelle Winterhagen,Christina Berens,Jens Müller,Johannes Oldenburg,Bernd Pötzsch
View Articletitled, In vivo thrombin generation and subsequent APC formation are increased in factor V Leiden carriers
Supplemental data

BLOOD WORK

A clandestine worm
Clinical Trials & Observations
Charles Bescond,Marion Eveillard
View Articletitled, A clandestine worm
Systemic mastocytosis with concurrent multiple myeloma
Ashvind A. Prabahran,Surender K. Juneja
View Articletitled, Systemic mastocytosis with concurrent multiple myeloma

ERRATUM

Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102-1108.
View Articletitled, Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <em>Blood.</em> 2016;127(9):1102-1108.
  • Cover Image

    Cover Image

    issue cover

    Interleukin-18 (IL-18) distinguishes and drives macrophage activation syndrome, particularly in patients carrying inflammasome-activating NLRC4 mutations. An activating Nlrc4 mutation in mice drives small intestinal epithelial IL-18 secretion and epithelial proliferation (pictured, green nuclei have recently divided, incorporating EdU [5-ethynyl-2'-deoxyuridine]; blue/DAPI [4',6-diamidino-2-phenylindole] stains all nuclei). See the article by Weiss et al on page 1442.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkTable of Contents
  • PDF Icon PDF LinkBack Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Licking the wound with procoagulant vesicles
Approaching Hypercalcemia in Monoclonal Gammopathy of Undetermined Significance: Insights from the iStopMM study
CAR T-cells in autoimmunity: game changer or stepping stone?
Long-Term Efficacy and Safety of Danicopan as Add-On Therapy to Ravulizumab or Eculizumab in PNH With Significant EVH
How I treat quantitative fibrinogen disorders

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals